Moderna Merck mRNA Cancer Vaccine and Keytruda for Resected Melanoma Adjuvant Therapy

Clip title: How Big of a Deal is this Cancer Vaccine? Author / channel: Hank Green URL: https://www.youtube.com/watch?v=DgeRVUSuGvQ

Summary

In a significant development for cancer treatment, Moderna and Merck recently announced positive Phase 3 trial results for a personalized mRNA cancer vaccine (Intismeran Autogene, also known as mRNA-4157 or V940) combined with Keytruda (pembrolizumab). The video’s presenter, with a background in cancer biology, acknowledges the widespread excitement surrounding this news while also cautioning against oversimplified or misinformed interpretations. His goal is to clarify the scientific details of the trial and explore whether this marks a breakthrough for a specific type of cancer or signals a broader shift in cancer therapy. He concludes that while it’s not a universal cure, it represents a highly promising step that could indeed impact a wider range of cancers.

The INTERPATH-001 Phase 3 trial involved over 1,000 patients with completely resected Stage IIB-IV melanoma. “Completely resected” is a critical detail, meaning all visible cancer had been surgically removed, and the treatment served as an adjuvant therapy to prevent recurrence. The combination therapy met its primary endpoint of Recurrence-Free Survival (RFS) and a key secondary endpoint of Distant Metastasis-Free Survival (DMFS), demonstrating statistically and clinically meaningful improvements compared to Keytruda alone. Keytruda, a checkpoint inhibitor, works by blocking cancer cells’ ability to “hide” from the immune system by neutralizing signals (PD-1/PD-L1) that tell T-cells to stand down. Melanoma, known for its high mutational burden, is particularly susceptible to Keytruda due to its reliance on this immune evasion pathway.

The individualized mRNA vaccine complements Keytruda by actively training the immune system to target specific cancer cells. Our bodies naturally display fragments of internal proteins on cell surfaces via MHC Class I molecules, allowing the immune system to monitor cell health. Cancer cells, due to mutations, produce abnormal proteins or neoantigens. Melanoma, with its high mutational burden, presents a wealth of these unique neoantigens. The personalized vaccine’s process involves sequencing a patient’s tumor genome, using machine learning to predict the most immunogenic neoantigens, and then creating an mRNA vaccine that instructs the patient’s cells to produce these specific neoantigens. This effectively “teaches” the immune system’s T-cells to recognize and attack any remaining cancer cells displaying these unique markers. The rapid manufacturing capabilities of mRNA technology are crucial for this personalized approach.

While not a complete cure for all melanoma patients, the results are significant, showing a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death in earlier Phase 2b data. The broader implication of this therapy is particularly exciting: a small Phase 1 trial (conducted by BioNTech) using a similar personalized mRNA vaccine for pancreatic cancer patients (who also had surgically resected tumors) showed promising results. This is noteworthy because pancreatic cancer typically has a much lower mutational burden than melanoma, making it a less obvious candidate for this type of therapy. This success suggests that individualized neoantigen therapies could potentially benefit a wider spectrum of cancers beyond those with high mutational loads, such as lung cancer in smokers. This represents a significant advancement in precision medicine, offering the potential for less toxic and more targeted treatments than traditional chemotherapy, though challenges such as cost, side effect management, and further refinement of neoantigen identification algorithms remain.

Video Description & Links

Description

Moderna and Merck announced that they have completed a Phase 3 trial for a vaccine that significantly improves outcomes for people with melanoma (the most deadly form of skin cancer.)

This is very exciting…but /how/ exciting is it? And could it mean not just a new cancer therapy but a whole new /class/ of cancer therapies? I think it could very well be both.

SOURCES

Melanoma staging and mutations https://www.cancer.gov/types/skin/patient/melanoma-treatment-pdq https://pmc.ncbi.nlm.nih.gov/articles/PMC4580370/

Keytruda and checkpoint inhibitors https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors https://www.cancer.gov/about-cancer/treatment/drugs/pembrolizumab

immune-mediated colitis https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287

MHC I https://www.ncbi.nlm.nih.gov/books/NBK459467/

https://doi.org/10.1200/JCO-26-00835

The paper that identified the weird effect with covid vaccines and keytruda https://www.nature.com/articles/s41586-025-09655-y?utm_id=97760_v0_s00_e0_tv4